Actual Medicinal Product (AMP) Adartrel 500microgram tablets (GlaxoSmithKline UK Ltd)
Stability Information
- Stability
-
There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label. Mitigation measures may need to be considered. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
- Notes
-
Protect from light. Store in original package.
- Generic
- Ropinirole
- Formulation
- Ropinirole 500microgram tablets
-
Ropinirole
-
Ropinirole 500microgram tablets
-
Adartrel 500microgram tablets (GlaxoSmithKline UK Ltd)
-
-
Adartrel 500microgram tablets (Sigma Pharmaceuticals Plc)
Ropinirole 500microgram tablets (Viatris UK Healthcare Ltd)